Sands Capital Management LLC Acquires 340,245 Shares of argenex SE $ARGX

Sands Capital Management LLC boosted its holdings in shares of argenex SE (NASDAQ:ARGX) by 2,046.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 356,870 shares of the company’s stock after purchasing an additional 340,245 shares during the period. Sands Capital Management LLC’s holdings in argenex were worth $300,110,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. lifted its holdings in argenex by 2.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after acquiring an additional 12 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in argenex by 0.9% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after acquiring an additional 12 shares in the last quarter. CI Investments Inc. lifted its holdings in argenex by 2.6% during the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after acquiring an additional 12 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in argenex by 3.4% during the third quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after acquiring an additional 13 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in argenex by 12.7% during the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after acquiring an additional 13 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wells Fargo & Company lifted their target price on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Glj Research upgraded argenex to a “strong-buy” rating in a report on Friday, April 3rd. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright boosted their price target on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Citizens Jmp boosted their price target on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Price Performance

Shares of argenex stock opened at $893.52 on Monday. The firm has a market cap of $55.57 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. The stock’s 50-day moving average is $812.09 and its 200-day moving average is $811.50. argenex SE has a one year low of $510.05 and a one year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. On average, equities analysts expect that argenex SE will post 26.19 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.